Atjaunināt sīkdatņu piekrišanu

Nurse's Chemotherapy Quick Pocket Reference [Mīkstie vāki]

  • Formāts: Paperback / softback, 208 pages, weight: 227 g
  • Izdošanas datums: 11-Nov-2008
  • Izdevniecība: Jones and Bartlett Publishers, Inc
  • ISBN-10: 0763758248
  • ISBN-13: 9780763758240
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 102,83 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
  • Formāts: Paperback / softback, 208 pages, weight: 227 g
  • Izdošanas datums: 11-Nov-2008
  • Izdevniecība: Jones and Bartlett Publishers, Inc
  • ISBN-10: 0763758248
  • ISBN-13: 9780763758240
Citas grāmatas par šo tēmu:
Nurse's Chemotherapy Quick Pocket Reference is a portable, quick-reference guide that provides quick access to the essentials of chemotherapy dosing administration and is arranged alphabetically by cancer type. This resource covers drug information for over 4 cancer types including bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, leukemia, lung cancer, ovarian cancer, prostate cancer, thyroid cancer, and more, and includes pre-treatment information, chair time, and major side effects for each drug entry. All the chemotherapy drug information you need in the palm of your hand!
Preface ix
Anal Cancer
1(4)
Metastatic Disease and/or Salvage Chemotherapy
2(3)
Biliary Cancer
5(2)
Bladder Cancer
7(6)
Combination Regimens
7(4)
Single-Agent Regimens
11(2)
Bone Metastasis
13(2)
Brain Cancer
15(6)
Adjuvant Therapy
15(1)
Combination Regimens
15(1)
Single-Agent Regimens
16(1)
Advanced Disease
17(1)
Combination Regimens
17(1)
Single-Agent Regimens
17(4)
Breast Cancer
21(12)
Neoadjuvant Therapy
21(1)
Combination Regimens
21(1)
Adjuvant Therapy
22(1)
Combination Regimens
22(7)
Single-Agent Regimens
29(4)
Metastatic Breast Cancer
33(18)
Combination Regimens
33(11)
Single-Agent Regimens
44(7)
Cancer of Unknown Primary
51(4)
Carcinoid Tumors
55(2)
Combination Regimens
55(1)
Single-Agent Regimens
56(1)
Cervical Cancer
57(6)
Combination Regimens
57(4)
Single-Agent Regimens
61(2)
Colorectal Cancer
63(20)
Neoadjuvant Combined Modality Therapy
63(1)
Combination Regimens
63(4)
Adjuvant Therapy
64(3)
Metastatic Disease
67(1)
Combination Regimens
67(11)
Hepatic Artery Infusion
78(1)
Single-Agent Regimens
78(5)
Endometrial Cancer
83(6)
Combination Regimens
83(2)
Single-Agent Regimens
85(4)
Esophageal Cancer
89(4)
Combination Regimens
89(3)
Metastatic Disease
90(2)
Single-Agent Regimens
92(1)
Gastric Cancer
93(8)
Adjuvant Therapy
93(1)
Combination Regimens
94(4)
Single-Agent Regimens
98(3)
Gastrointestinal Stromal Tumor (GIST)
101(2)
Single-Agent Regimens
101(2)
Head and Neck Cancer
103(8)
Combination Regimens
103(5)
Single-Agent Regimens
108(3)
Hepatocellular Cancer
111(2)
Single-Agent Regimens
111(2)
Kaposi's Sarcoma
113(4)
Combination Regimens
113(1)
Single-Agent Regimens
114(3)
Leukemia: Acute Lymphocytic Leukemia (All)
117(2)
Linker Regimen
117(1)
Induction Therapy
117(1)
Consolidation Therapy
118(1)
Maintenance Therapy
119(1)
CNS Prophylaxis
119(1)
Larson Regimen
119(6)
Induction Therapy (Weeks 1-4)
120(1)
Early Intensification (Weeks 5-12)
120(1)
CNS Prophylaxis and Interim Maintenance (Weeks 13-25)
120(1)
Late Intensification (Weeks 26-33)
120(1)
Prolonged Maintenance
121(1)
Hyper-Cvad Regimen
121(1)
Induction Therapy
122(1)
High-Dose Methotrexate/Cytarabine
122(1)
CNS Prophylaxis
122(1)
Supportive Care
123(1)
Single-Agent Regimens
123(2)
Leukemia: Acute Lymphocytic Leukemia: Relapsed or Refractory PH + All
125(2)
Single-Agent Regimens
125(2)
Leukemia: Acute Myelogenous Leukemia (AML)
127(6)
Induction Regimens
127(2)
Consolidation Regimens
129(1)
Single-Agent Regimens
130(3)
Relapse AML
131(2)
Leukemia: Acute Promyelocytic Leukemia (APL)
133(4)
Combination Regimens
133(1)
Single-Agent Regimens
134(3)
Leukemia: Chronic Lymphocytic Leukemia (CLL)
137(8)
Combination Regimens
137(3)
Single-Agent Regimens
140(5)
Leukemia: Chronic Myelogenous Leukemia (CML)
145(4)
Combination Regimens
145(1)
Single-Agent Regimens
145(4)
Leukemia: Cutaneous T-Cell Leukemia (CTCL)
149(2)
Leukemia: Hairy Cell Leukemia
151(2)
Lung Cancer: Non-Small Cell Lung Cancer
153(12)
Adjuvant Therapy
153(1)
Combination Regimens
153(1)
Metastatic Disease
154(1)
Combination Regimens
154(6)
Single-Agent Regimens
160(5)
Lung Cancer: Small Cell Lung Cancer
165(4)
Combination Regimens
165(3)
Single-Agent Regimens
168(1)
Lymphoma: Hodgkin's Disease
169(8)
Combination Regimens
169(6)
Single-Agent Regimens
175(2)
Lymphoma: Non-Hodgkin's Lymphoma
177(22)
Low-Grade
177(1)
Combination Regimens
177(9)
Intermediate-Grade
180(5)
High-Grade
185(1)
CNS Prophylaxis
186(8)
Mantle Cell Lymphoma
189(1)
Cd20+ B-Cell Lymphomas
189(1)
Salvage Regimens
190(3)
Primary CNS Lymphoma
193(1)
Single-Agent Regimens
194(5)
Lymphoma: Cutaneous T-Cell Lymphoma (CTCL)
199(2)
Single-Agent Regimens
199(2)
Malignant Melanoma
201(6)
Adjuvant Therapy
201(1)
Metastatic Disease
201(1)
Combination Regimens
201(3)
Single-Agent Regimens
204(3)
Malignant Mesothelioma
207(4)
Combination Regimens
207(4)
Multiple Myeloma
211(6)
Combination Regimens
211(4)
Single-Agent Regimens
215(2)
Myelodysplastic Syndrome
217(4)
Single-Agent Regimens
217(4)
Ovarian Cancer
221(6)
Combination Regimens
221(4)
Single-Agent Regimens
225(2)
Ovarian Cancer: Germ Cell
227(2)
Combination Regimens
227(2)
Pancreatic Cancer
229(6)
Locally Advanced Disease
229(1)
Metastatic Disease
229(1)
Combination Regimens
229(5)
Single-Agent Regimens
234(1)
Prostate Cancer
235(8)
Combination Regimens
235(3)
Single-Agent Regimens
238(5)
Renal Cell Cancer
243(4)
Combination Regimens
243(1)
Single-Agent Regimens
244(3)
Soft Tissue Sarcomas
247(4)
Combination Regimens
247(2)
Single-Agent Regimens
249(2)
Testicular Cancer
251(6)
Adjuvant Therapy
251(1)
Advanced Disease
251(2)
Salvage Regimens
253(1)
Stage 1 Seminoma
254(3)
Thymoma
257(2)
Thyroid Cancer
259(2)
Combination Regimens
259(1)
Single-Agent Regimens
259(2)
References 261